STX1A: A Potential Drug Target for Neurological and Psychiatric Conditions

Target Name: STX1A

NCBI ID: G6804

STX1A

STX1A: A Potential Drug Target for Neurological and Psychiatric Conditions

Syntaxin-1A (ISO Form 1) is a protein that is expressed in the brain and plays a critical role in the proper functioning of language and communication. It is a key protein that helps to coordinate the movement of nerve cells, allowing for smooth and efficient communication between different parts of the brain.

Recent studies have suggested that STX1A may be a drug target or biomarker for various neurological and psychiatric conditions, including Alzheimer's disease, Parkinson's disease, and depression. This is because the dysfunction of STX1A has been implicated in the development and progression of these conditions.

One of the key reasons for the potential of STX1A as a drug target is its involvement in the regulation of neural communication. Studies have shown that STX1A plays a role in the proper functioning of communication between different neurons in the brain, and that it is involved in the transmission of signals along these connections. This suggests that alterations in STX1A levels or function could disrupt this essential communication and contribute to the development of neurological conditions.

Another potential mechanism by which STX1A may be involved in the development of these conditions is its role in the regulation of neurotransmitter release. Studies have shown that STX1A is involved in the release of neurotransmitters, such as dopamine and serotonin, which are involved in the regulation of mood, emotion, and other aspects of brain function. Alterations in STX1A levels or function have been implicated in the regulation of neurotransmitter release, which could contribute to the development of psychiatric conditions.

In addition to its role in neural communication and neurotransmitter release, STX1A has also been shown to be involved in the regulation of cellular signaling. Studies have shown that STX1A plays a role in the regulation of cell signaling pathways, which are involved in the regulation of cellular processes such as cell growth, differentiation, and survival. This suggests that alterations in STX1A levels or function could contribute to the development of various diseases.

Overall, the potential of STX1A as a drug target or biomarker for neurological and psychiatric conditions is significant. Its involvement in the regulation of neural communication, neurotransmitter release, and cellular signaling suggests pathways that it may be a useful target for the development of new treatments for a variety of psychiatric and neurological conditions. Further research is needed to fully understand the role of STX1A in these conditions and to develop effective treatments.

Protein Name: Syntaxin 1A

Functions: Plays an essential role in hormone and neurotransmitter calcium-dependent exocytosis and endocytosis (PubMed:26635000). Part of the SNARE (Soluble NSF Attachment Receptor) complex composed of SNAP25, STX1A and VAMP2 which mediates the fusion of synaptic vesicles with the presynaptic plasma membrane. STX1A and SNAP25 are localized on the plasma membrane while VAMP2 resides in synaptic vesicles. The pairing of the three SNAREs from the N-terminal SNARE motifs to the C-terminal anchors leads to the formation of the SNARE complex, which brings membranes into close proximity and results in final fusion. Participates in the calcium-dependent regulation of acrosomal exocytosis in sperm (PubMed:23091057). Also plays an important role in the exocytosis of hormones such as insulin or glucagon-like peptide 1 (GLP-1) (By similarity)

The "STX1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STX1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets